An interventional study of Educational Intervention and Educational Intervention in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia and Lymphoblastic Lymphoma, sponsored by City of Hope Medical Center. Active, not recruiting at 3 sites in United States. Open to participants aged 5 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by City of Hope Medical Center · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by City of Hope Medical Center — 10 open to participants now, 28 under way, none of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · City of Hope Medical Center.
Among the 55 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by City of Hope Medical Center, this one is the 5th largest by enrollment of the 50 interventional ones that give a count, is the only one that started in 2017, is one of 8 with no phase, reaches primary completion later than 18 of the 27 other live ones, and was the 32nd registered.
2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →10 of the 55 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by City of Hope Medical Center are open now, in 1 country. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18–75 · Healthy volunteers
City of Hope Medical Center · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18–54
City of Hope Medical Center · Sites in United States
Ages 18–70
By country, each count listing its studies:
Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.
This study: 5 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 20
First in 2000; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 214 is above the median of 40 across 1,953 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 32 across the 50 interventional studies, 153 across the 5 observational. Of the 24 that completed or were terminated, 8 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
City of Hope Medical Center is the lead sponsor of 677 studies on the registry; 181 are open to participants now.
Of its 31 completed or terminated interventional studies of FDA-regulated products, 12 (39%) have results posted.
11 of the studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by City of Hope Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06059391City of Hope Medical CenterCMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant | 2027-01-01 |
| NCT05364762City of Hope Medical CenterAdding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants | 2027-03-25 |
| NCT02094794City of Hope Medical CenterTotal Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML | 2027-05-04 |
| NCT04262843City of Hope Medical CenterTotal Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia | 2027-05-11 |
| NCT04537871City of Hope Medical CenterCardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study | 2027-05-25 |
Add all 11 to your calendar (.ics) → With an account.
Among the 55 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by City of Hope Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized clinical trial studies how well a high-intensity intervention parenting program works in improving learning and school functioning in Latino children with acute leukemia or lymphoblastic lymphoma. A high-intensity intervention program may help doctors to see whether training parents or caregivers in specific parenting skills and "pro-learning" behaviors will result in better learning and school outcomes for Latino children with acute leukemia or lymphoblastic lymphoma. It is not yet known if a high-intensity intervention program is more beneficial than a standard of care lower intensity parenting intervention.
PRIMARY OBJECTIVES:
I. Determine the effectiveness of an enhanced parenting intervention, high-intensity intervention program (HIP), on pediatric cancer survivors' learning and school health-related quality of life (HRQOL) outcomes up to 12 months post enrollment.
II. Determine the effectiveness of HIP on the "pro-learning" efficacy of parents of pediatric cancer survivors up to 12 months post enrollment.
III. Examine the extent to which the parent's increases in personal efficacy and use of "pro-learning" behaviors correlate with the child's school HRQOL and academic performance.
IV. Obtain preliminary data on the relationships between family stress and the Val66Met polymorphism of brain-derived neurotrophic factor (BDNF) with neurocognitive and health-related quality of life (HRQOL) outcomes in Latino children treated with CNS-directed therapies for cancer.
V. Conduct preliminary analysis on the interaction between family stress and the BDNF Met polymorphism when predicting cognitive and HRQOL outcomes in Latino children treated for cancer.
EXPLORATORY OBJECTIVES:
I. Explore the associations between neurocognitive performance and polymorphisms in candidate genes previously reported to explain cognitive variability in childhood cancer survivors (e.g., the catechol-O-methyltransferase Val158Met polymorphism and the nitric oxide synthase [NOS3] 894T allele) or involved in the stress response (e.g., the Serotonin transporter rs25531 and the Glucocorticoid receptor rs6190).
OUTLINE: Parents or caregivers are randomized to 1 of 2 arms.
ARM I: Parents or caregivers attend standard of care lower intensity intervention program (LIP) consisting of a meeting to review results of a neurocognitive evaluation and to discuss recommendations for optimal learning and school performance for 1 session.
ARM II: Parents or caregivers attend HIP consisting of individual parental skill training sessions with a bilingual therapist over 60-90 minutes every 2 weeks for a total of 8 sessions.
After study enrollment, patients are followed up for 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Parents or caregivers attend standard of care LIP consisting of a meeting to review results of a neurocognitive evaluation and to discuss recommendations for optimal learning and school performance for 1 session.
Other: Educational Intervention · Other: Quality-of-Life Assessment · Other: Questionnaire Administration
Parents or caregivers attend HIP consisting of individual parental skill training sessions with a bilingual therapist over 60-90 minutes every 2 weeks for a total of 8 sessions.
Other: Educational Intervention · Other: Quality-of-Life Assessment · Other: Questionnaire Administration
Attend standard of care LIP
Also known as: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational
Attend HIP
Also known as: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational
Ancillary studies
Also known as: Quality of Life Assessment
Ancillary studies
Change in child's health-related quality of life school functioning
Measured by the parent-reported Pediatric Quality of Life Inventory school domain.
Time frame: Baseline up to 12 months
Change in parental efficacy
Measured by the Efficacy scale from the Parent Knowledge, Beliefs and Behaviors Questionnaire-3rd Revision (PBQ-R3).
Time frame: Baseline up to 12 months
Objective academic performance (Child)
Measured by WIAT: reading and math scores and classroom grades from school report cards.
Time frame: Up to 12 months
Attention performance (Child)
Measured by the Conners Parent Report Attention subscale.
Time frame: Up to 12 months
Frequency of pro-learning behaviors (Parent)
Measured by PBQ-R3 Behaviors Scale.
Time frame: Up to 12 months
Frequency of pro-learning behaviors (Parent)
Measured by the Parents' weekly time spent with child in pro-learning behaviors and activities.
Time frame: Up to 12 months
Knowledge of pro-learning parenting (Parent)
Measured by PBQ-R3 Knowledge scale.
Time frame: Up to 12 months
Children's scores on other neurocognitive tests as assessed by learning, memory, and processing speed
Time frame: Up to 12 months
Parental reports of their children's HRQOL as measured by the PedsQL parent proxy questionnaire
Time frame: Up to 12 months
Started Oct 2017 (actual). Primary completion is estimated for Oct 2027, 119 months after the start.
Of 207 non-industry interventional studies with no phase under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 66. This study's planned 119 months is above that.
Counting every sponsor, half of 214 studies reached it within 32 months; a quarter within 12 and three quarters within 66.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Oct 2026 → Oct 2027 and completion Oct 2026 → Oct 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Precursor Cell Lymphoblastic Leukemia-Lymphoma →